Targeted Oncology: Transfusion independence at 24 weeks linked to improved OS on momelotinib in myelofibrosis Shared By: contributorJune 11, 2021 Dr. Ruben Mesa, executive director of the Mays Cancer Center, is quoted in this Targeted Oncology story. Read the story. Share This Article!
